positive results likely to push this stock significantly higher ,,results expected within 4 weeks . The drug is already partnered with pharma giant Boehringer Ingelheim . Competitors like Genfit , Intercept and Madrigal all valued north of US$500+ Million while Pharmaxis has a laughable valuation of only US$ 54 Million . Positive readout could push stock closer to $1 .GL
"SunTrust Robinson Humphrey's analyst Edward Nash, who has called NASH "one of the last untapped multibillion-dollar therapeutic areas," forecasts the space to grow to more than $5 billion in the U.S. alone by 2028. Research and consulting firm GlobalData estimates the NASH space across seven major markets -- the U.S., France, Germany, Italy, Spain, the U.K. and Japan -- is set to rise to $25.3 billion by 2026.
As markets for diseases such as diabetes and hepatitis C become crowded, companies are looking to NASH for their next big break."
- Forums
- ASX - By Stock
- SNT
- NASH Phase 2 results imminent --A $20+ BILLION Market
NASH Phase 2 results imminent --A $20+ BILLION Market
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.2¢ |
Change
-0.001(4.35%) |
Mkt cap ! $26.26M |
Open | High | Low | Value | Volume |
2.3¢ | 2.3¢ | 2.2¢ | $13.51K | 608.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 282901 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.5¢ | 43870 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 169265 | 0.022 |
5 | 1736248 | 0.021 |
12 | 3101008 | 0.020 |
3 | 1289988 | 0.019 |
3 | 1002999 | 0.018 |
Price($) | Vol. | No. |
---|---|---|
0.025 | 43870 | 2 |
0.026 | 50000 | 1 |
0.027 | 200000 | 1 |
0.028 | 500000 | 1 |
0.029 | 347870 | 2 |
Last trade - 15.58pm 27/06/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |